Advisory Committee on Heritable Disorders in Newborns and Children

Advisory Committee on Heritable Disorders in Newborns and Children
Name	Advisory Committee on Heritable Disorders in Newborns and Children
Formation	2005
Type	Federal advisory committee
Purpose	Newborn screening policy recommendations
Headquarters	Bethesda, Maryland
Parent organization	Department of Health and Human Services
Website	N/A

Advisory Committee on Heritable Disorders in Newborns and Children is a federal advisory committee that provides guidance on screening, diagnosis, and follow-up for heritable disorders detected in newborns and children. The committee evaluates scientific evidence, technology, and public health practice to inform Department of Health and Human Services policy, state programs, and stakeholder organizations. Its work intersects with clinical specialties, legal frameworks, and patient advocacy groups across the United States.

Background and Establishment

The committee was established within the framework of federal initiatives that involved actors such as Secretary of Health and Human Services, National Institutes of Health, Centers for Disease Control and Prevention, and the Health Resources and Services Administration. Its origins trace to policy debates involving figures like George W. Bush administration officials and bipartisan legislative efforts in the United States Congress that responded to recommendations from panels including the Institute of Medicine and experts connected to March of Dimes. Early proponents referenced models from entities such as United Kingdom National Screening Committee, European Centre for Disease Prevention and Control, and newborn screening systems in California, New York (state), and Wisconsin. The committee’s charter reflects input from stakeholders including the American Academy of Pediatrics, American College of Medical Genetics and Genomics, and patient groups such as Genetic Alliance.

Mandate and Functions

The committee’s mandate encompasses evidence review, test assessment, and policy recommendation. It synthesizes data from sources like PubMed, reports produced by the Food and Drug Administration, and surveillance systems managed by the Centers for Disease Control and Prevention. Functions include developing criteria for adding conditions to recommended screening panels, advising on confirmatory testing pathways that involve laboratories accredited by College of American Pathologists, and recommending follow-up protocols used by state public health departments such as those in New Jersey and Texas. The committee also addresses implementation issues that relate to clinical programs at institutions like Johns Hopkins Hospital and Boston Children’s Hospital, and intersects with ethics discussions that involve organizations such as The Hastings Center.

Membership and Governance

Membership comprises clinicians, laboratory scientists, geneticists, ethicists, public health officials, and family representatives appointed by the Secretary of Health and Human Services. Notable professional affiliations represented include American Medical Association, American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, and academic centers including Harvard Medical School and Stanford University School of Medicine. Governance follows federal advisory committee statutes under the Federal Advisory Committee Act and involves liaisons from agencies like the National Human Genome Research Institute and the Agency for Healthcare Research and Quality. Terms and conflict-of-interest rules reflect practices observed in panels such as those convened by the National Academies of Sciences, Engineering, and Medicine.

Recommendations and Policy Impact

The committee’s recommendations influence the Recommended Uniform Screening Panel (RUSP) and have driven additions of conditions such as severe combined immunodeficiency and critical congenital heart disease, affecting screening practice across states including Florida and California. Its policy outputs inform guidance adopted by professional societies like the American College of Medical Genetics and Genomics and integrate with reimbursement discussions involving the Centers for Medicare & Medicaid Services. Impact extends to research funding priorities at the National Institutes of Health and to regulatory considerations addressed by the Food and Drug Administration for diagnostic platforms developed by companies in regions such as Silicon Valley.

Meetings and Reports

The committee convenes public meetings where stakeholders including representatives from March of Dimes, Clinton Foundation, and state newborn screening programs present evidence. Agendas and white papers have addressed topics spanning biochemical screening, genomic sequencing pilots involving institutions like University of California, San Francisco, and follow-up care coordination with children’s hospitals such as Gundersen Health System. Reports and meeting minutes are prepared for review by officials including the Surgeon General and are discussed at forums like the American Society of Human Genetics annual meeting.

Controversies and Ethical Considerations

Controversies have centered on issues such as the inclusion of genomic sequencing, consent models akin to debates involving Theranos-era diagnostics, data privacy concerns similar to disputes involving 23andMe, and the use of residual bloodspots, which prompted litigation and policy changes in states like Minnesota and Texas. Ethical debates invoke principles discussed in documents by Belmont Report-aligned frameworks and organizations such as The Hastings Center, with tensions between public health benefit and parental autonomy raised in venues including state legislatures and courts like those in New York (state).

International and State-Level Coordination

The committee’s recommendations interface with international bodies such as the World Health Organization and regional programs in Europe and Canada, and they inform interstate collaborations like the Association of Public Health Laboratories and consortia among states including Massachusetts, Pennsylvania, and Ohio. Coordination addresses harmonization of panels, quality standards consistent with ISO norms, and cross-jurisdictional data-sharing frameworks modeled after initiatives coordinated by entities such as Public Health England.

Category:United States federal advisory committees